niphon/iStock by way of Getty Pictures
- Immunovant (IMVT) rose 14% amid some takeover hypothesis.
- There’s hypothesis that Immunovant has attracted takeover curiosity, in keeping with merchants, who cited a Betaville “raw” alert that was circulating on Thursday. One of many firms all in favour of shopping for Immunovant is Roivant (ROIV), Immunovant’s largest shareholder.
- Immunovant (IMVT) has a market cap of $3.8 billion.
- Immunovant (IMVT) is ready to report its Q3 outcomes on Nov. 10.
